About US
Contact us
-
ADC Therapeutics taps Avid for production of its new blood cancer med ZynlontaWith an FDA approval in hand, ADC Therapeutics has enlistedits old friend Avid Bioservices to rev up commercial manufacturing for its new drug Zynlonta. ADCtapped Avid, which started handlingcl2021/5/21
-
AstraZeneca hits U.K. antitrust review with $39B Alexion buy after U.S. FTC clearanceAstraZeneca investors breathed a sigh of relief last month when the U.S. antitrust watchdog cleared the company’s proposed $39 billion acquisition of Alexion Pharma. Turns out, that go-ahead was no g2021/5/21
-
Lilly, Innovent's Tyvyt nabs FDA review in front-line lung cancer. Could price pressure finally reach the PD-1/L1 class?Tuesday, Innovent Biologics and partner Eli Lilly said the FDA hadacceptedtheir application for Tyvyt, or sintilimab, in combination with Lilly’s own Alimta and platinum chemotherapy for newly diagno2021/5/19
-
Novartis' Sandoz embarks on €150M antibiotics manufacturing upgrade in EuropeWhile much of the pharma industry has shifted its focusaway from antibiotics, Novartis' Sandoz unit is doing just the opposite and is chartingnext steps in amulti-year manufacturing upgrade in Europe2021/5/19
-
WuXi Bio steps up its ADC manufacturing game with a new, dedicated subsidiaryAntibody-drug conjugates are rushing to the fore. Of 11 ADCs on the market today, six have been approved since 2019. That means demand for ADC manufacturing is on the rise—and now answering t2021/5/17
-
Sandoz's Enbrel biosim case turned away at SCOTUS, giving Amgen's blockbuster 8 more years of free reinAfter back-to-back losses in court, Novartis’ generics outfit Sandoz had hoped the U.S. Supreme Court would take up itslong shot biosimilarscase against Enbrel maker Amgen. But now that effort has fa2021/5/17
-
Seagen's set for major growth, but Padcev sales estimates are a 'tall order': analystSeagen is one of the industry’s antibody-drug conjugate powerhouses. Its growth hinges on bladder cancer drug Padcev and small-molecule breast cancer med Tukysa, which carry blockbuster sales estimat2021/5/14
-
Sanofi, touting new data, sees 'best-in-class' case for Dupixent in pediatric asthmaSanofi's Dupixent is already off and running in several key markets—including eczema and adult asthma—and churning up blockbuster sales. Now, with a potential FDA approval in childhood asthma forthco2021/5/14
-
J&J, Bayer pad case for Xarelto in post-surgery artery disease patientsWith an approvalfiling alreadyon the FDA’s docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in arterydisease patients after surgery. In long-t2021/5/12
-
Regeneron's Evkeeza aces triglyceride control, but only in certain patientsRegeneron’s new med Evkeeza already sports an approval in the ultra-rare disease homozygous familial hypercholesterolemia, which is associated with extreme levels of cholesterol. But thanks to compet2021/5/12